Presentation is loading. Please wait.

Presentation is loading. Please wait.

The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial  Tilo Biedermann,

Published by희웅 조 Modified over 5 years ago

Similar presentations

Presentation on theme: "The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial  Tilo Biedermann,"— Presentation transcript:

1 The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial  Tilo Biedermann, MD, Piotr Kuna, MD, PhD, Petr Panzner, MD, PhD, Erkka Valovirta, MD, Morgan Andersson, MD, Frederic de Blay, MD, PhD, Dorthe Thrane, MSc, Sanja Hald Jacobsen, MSc, Brian Sonne Stage, MSc, Lone Winther, MD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 3, Pages e6 (March 2019) DOI: /j.jaci Copyright © 2019 The Authors Terms and Conditions

2 Journal of Allergy and Clinical Immunology 2019 143, 1058-1066
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

3 Fig 1 Trial design. Subjects were treated for at least 16 weeks before and during the 2017 TPS. Efficacy was assessed throughout the TPS. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

4 Fig 2 Subject disposition. *Primarily subjects who withdrew consent or were lost to follow-up before randomization. **Subjects with a valid value for the primary end point in the BPS. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

5 Fig 3 Primary and key secondary end points.
Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

6 Fig 4 Proportion of mild and severe days during the BPS. Mild days, Days without intake of antihistamine tablet/eyedrops and no single symptom scoring greater than 1; Odds ratio, SQ tree SLIT-tablet/placebo; Severe days, days with DSS of 6 or greater and 2 or more moderate or 1 severe symptom. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

7 Fig 5 Immunology. Change from baseline in birch-specific IgE and IgG4 levels. Adjusted means with 95% CIs are shown. *Statistically significant difference from placebo: P < .0001. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

8 Fig 6 Percentage of subjects with the most frequent treatment-related AEs (experienced by ≥ 5% of subjects treated with SQ tree SLIT-tablet). Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

9 Fig E1 Post hoc analysis of average TCS, DMS, and DSS during the alder and hazel seasons. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

10 Fig E2 Median onset and duration of most frequent treatment-related AEs (experienced by ≥ 5% of subjects treated with SQ tree SLIT-tablet). Left, Median onset and duration of AE. Duration is given as time from onset until resolution (reoccurring AEs given from first to last day of appearance). Overlapping symbols indicate resolution on same day of occurrence. Right, Median onset of AE for AEs starting on the first day of treatment. Journal of Allergy and Clinical Immunology  , e6DOI: ( /j.jaci ) Copyright © 2019 The Authors Terms and Conditions

Download ppt "The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial  Tilo Biedermann,"

Similar presentations

Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis  Kristian Reich, MD, PhD, Julia Deinzer,

Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis  Kristian Reich, MD, PhD, Julia Deinzer,
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.

Efficacy and tolerability of systemic methylprednisolone in children and adolescents with chronic rhinosinusitis: A double-blind, placebo-controlled randomized.
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,

A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy  Satya D. Narisety,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,

Sublingual immunotherapy for peanut allergy: A randomized, double-blind, placebo- controlled multicenter trial  David M. Fleischer, MD, A. Wesley Burks,
Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K

Claus Bachert, PhD, Ana R. Sousa, PhD, Valerie J. Lund, MD, Glenis K
Stacie M. Jones, MD, Scott H. Sicherer, MD, A

Stacie M. Jones, MD, Scott H. Sicherer, MD, A
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.

Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical.
Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,

Safety, clinical, and immunologic efficacy of a Chinese herbal medicine (Food Allergy Herbal Formula-2) for food allergy  Julie Wang, MD, Stacie M. Jones,
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,

Efficacy and Safety of the Seven-Day Buprenorphine Transdermal System in Opioid- Naïve Patients with Moderate to Severe Chronic Low Back Pain: An Enriched,
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,

The effects of house dust mite sublingual immunotherapy tablet on immunologic biomarkers and nasal allergen challenge symptoms  Natasha C. Gunawardana,
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma  Eric D. Bateman, MD, Udo-Michael.

Similar presentations

Ads by Google